The Global Health Body Raises Alert Over Acute Scarcity of Weight-Loss Jabs
Fewer than one in 10 patients who could benefit from GLP-1 drugs such as Wegovy can access them, states the WHO as it issues its initial guidance on the medications.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is urging increased and just availability to these injectable treatments.
Based on forecasts, over two billion are projected to be living with obesity by 2030 without intervention.
"The latest guidance acknowledges that excess weight is a lifelong illness that can be managed with comprehensive and lifelong care," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are major obstacles to universal availability to the jabs that can aid individuals in losing significant weight, says the agency.
Weight-Loss Drug Supply Crisis
Even under the present most favorable outlook, the supply of GLP-1 therapies might only reach around 100 million people – fewer than 10% of the global need, as stated by the health organization.
The recommendation urges governments and firms to increase availability, via measures like licensing agreements.
A patent on a key compound – the main component of a leading brand – is due to expire in multiple nations in 2026.
How Weight-Loss Jabs Operate
These medications mimick a body's own hormone to slow digestion, suppress the appetite and increase feelings of fullness so individuals consume fewer calories.
Individuals usually start to lose weight after several weeks of commencing the once-weekly jabs.
Evidence suggests patients may put most of the weight back on within a year of discontinuing the medication, because their normal hunger resume.
To be overweight or obese raises your likelihood for contracting medical conditions, like diabetes, heart disease, stroke, and some cancers.
Obesity affects individuals in countries worldwide and was linked to millions of deaths worldwide in 2024, per the health agency.
